Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Nano-Phytopharmaceuticals in Inflammation

Author(s): Akhila Sivasankaran Nair* and Remya Kopilakkal

Volume 17, Issue 1, 2023

Published on: 10 February, 2023

Page: [31 - 38] Pages: 8

DOI: 10.2174/2772270817666230123121836

Price: $65

Abstract

Inflammation is a defense mechanism of the body against harmful stimuli/organisms. Even if it is the body’s defense mechanism, these mediators may affect different ways in the human body and can lead to chronic disorders. The most common treatment strategy for the acute type of inflammation mainly includes synthetic chemical drugs; Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressant drugs whereas these synthetic drugs have many side effects, adverse effects, and limitations. Herbal drugs can be a promising alternative to these synthetic drugs but they too have limitations. Recent advances in the nanotechnology field can be combined with herbal drugs to overcome the limitations. Research works done on topical nanophyto pharmaceuticals for anti-inflammatory activity were compiled and in all the studies, clear evidence is indicated for the increased penetration, distribution, and increased efficacy of phytopharmaceuticals when formulated into nano dosage forms. Considering the adverse effects and limitations of most widely used synthetic drugs, topical nano Phyto pharmaceuticals can play a pivotal role in the local and systemic delivery of promising phytoconstituents to a specific site of the body.

« Previous Next »
Graphical Abstract

[1]
Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998; 47 (Suppl. 2): 78-87.
[http://dx.doi.org/10.1007/s000110050284] [PMID: 9831328]
[2]
Pahwa R, Goyal A, Jialal I. Chronic Inflammation. Treasure Island, FL: StatPearls Publishing 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/
[3]
Osafo N, Agyare C, Obiri DD, Antwi A. Mechanism of action of nonsteroidal anti-inflammatory drugs. Nonsteroidal antiinflammatory drugs. London: IntechOpen 2017. Available from: http://www.intechopen.com/chapters/55279
[http://dx.doi.org/10.5772/68090]
[4]
McPherson ML, Cimino NM. Topical NSAID formulations. Pain Med 2013; 14 (Suppl. 1): S35-9.
[http://dx.doi.org/10.1111/pme.12288] [PMID: 24373109]
[5]
Yatoo MI, Gopalakrishnan A, Saxena A, et al. Anti-inflammatory drugs and herbs with special emphasis on herbal medicines for countering inflammatory diseases and disorders - A review. Recent Pat Inflamm Allergy Drug Discov 2018; 12(1): 39-58.
[http://dx.doi.org/10.2174/1872213X12666180115153635] [PMID: 29336271]
[6]
Zhang Q, Mochalin VN, Neitzel I, et al. Mechanical properties and biomineralization of multifunctional nanodiamond-PLLA composites for bone tissue engineering. Biomaterials 2012; 33(20): 5067-75.
[http://dx.doi.org/10.1016/j.biomaterials.2012.03.063] [PMID: 22494891]
[7]
Pelaz B, Alexiou C, Alvarez-Puebla RA, et al. Diverse applications of nanomedicine. ACS Nano 2017; 11(3): 2313-81.
[http://dx.doi.org/10.1021/acsnano.6b06040] [PMID: 28290206]
[8]
Rahman M, Beg S, Verma A, et al. Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery. J Pharm Pharmacol 2016; 69(1): 1-14.
[http://dx.doi.org/10.1111/jphp.12661] [PMID: 27774648]
[9]
Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules 2020; 25(9): 2193.
[http://dx.doi.org/10.3390/molecules25092193] [PMID: 32397080]
[10]
Vanti G. Recent strategies in nanodelivery systems for natural products: a review. Environ Chem Lett 2021; 19(6): 4311-26.
[http://dx.doi.org/10.1007/s10311-021-01276-x]
[11]
Khogta S, Patel J, Barve K, Londhe V. Herbal nano-formulations for topical delivery. J Herb Med 2020; 20100300
[http://dx.doi.org/10.1016/j.hermed.2019.100300]
[12]
Abdulbaqi IM, Darwis Y, Khan NAK, Assi RA, Khan AA. Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 2016; 11: 2279-304.
[http://dx.doi.org/10.2147/IJN.S105016] [PMID: 27307730]
[13]
Roberts MS, Mohammed Y, Pastore MN, et al. Topical and cutaneous delivery using nanosystems. J Control Release 2017; 247: 86-105.
[http://dx.doi.org/10.1016/j.jconrel.2016.12.022] [PMID: 28024914]
[14]
Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011; 82(12): 1807-21.
[http://dx.doi.org/10.1016/j.bcp.2011.07.093] [PMID: 21827739]
[15]
Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol 2002; 40(12): 1745-50.
[http://dx.doi.org/10.1016/S0278-6915(02)00169-2] [PMID: 12419687]
[16]
Crespy V, Williamson G. A review of the health effects of green tea catechins in in vivo animal models. J Nutr 2004; 134 (Suppl. 12): 3431S-40S.
[http://dx.doi.org/10.1093/jn/134.12.3431S] [PMID: 15570050]
[17]
Cai ZY, Li XM, Liang JP, et al. Bioavailability of tea catechins and its improvement. Molecules 2018; 23(9): 2346.
[http://dx.doi.org/10.3390/molecules23092346] [PMID: 30217074]
[18]
Shariare HM, Afnan K, Iqbal F, et al. Development and optimization of epigallocatechin-3-Gallate (EGCG) nano phytosome using design of experiment (DoE) and their in vivo anti-inflammatory studies. Molecules 2020; 25(22): 5453.
[http://dx.doi.org/10.3390/molecules25225453] [PMID: 33233756]
[19]
Rit BG, Ramesh PP, Jae KS. Apigenin and Naringenin: Natural Sources, Pharmacology and Role in Cancer Prevention Biochemistry research trends. New York: Nova Publishers 2015.
[20]
Shen LN, Zhang YT, Wang Q, Xu L, Feng NP. Enhanced in vitro and in vivo skin deposition of apigenin delivered using ethosomes. Int J Pharm 2014; 460(1-2): 280-8.
[http://dx.doi.org/10.1016/j.ijpharm.2013.11.017] [PMID: 24269286]
[21]
Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 2009; 11(3): 495-510.
[http://dx.doi.org/10.1208/s12248-009-9128-x] [PMID: 19590964]
[22]
Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76(11): 1590-611.
[http://dx.doi.org/10.1016/j.bcp.2008.08.008] [PMID: 18775680]
[23]
Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: An “old-age” disease with an “age-old” solution. Cancer Lett 2008; 267(1): 133-64.
[http://dx.doi.org/10.1016/j.canlet.2008.03.025] [PMID: 18462866]
[24]
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4(6): 807-18.
[http://dx.doi.org/10.1021/mp700113r] [PMID: 17999464]
[25]
Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010; 18(9): 1606-14.
[http://dx.doi.org/10.1038/mt.2010.105] [PMID: 20571541]
[26]
Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011; 12(3): 332-47.
[http://dx.doi.org/10.2174/138945011794815356] [PMID: 20955148]
[27]
Kundu JK, Surh YJ. Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm Res 2010; 27(6): 999-1013.
[http://dx.doi.org/10.1007/s11095-010-0096-8] [PMID: 20354764]
[28]
Basnet P, Hussain H, Tho I, Skalko-Basnet N. Liposomal delivery system enhances anti-inflammatory properties of curcumin. J Pharm Sci 2012; 101(2): 598-609.
[http://dx.doi.org/10.1002/jps.22785] [PMID: 21989712]
[29]
Leung KW, Wong AST. Pharmacology of ginsenosides: A literature review. Chin Med 5 20(2010)
[http://dx.doi.org/10.1186/1749-8546-5-20]
[30]
Choi JH, Cho SH, Yun JJ, Yu YB, Cho CW. Ethosomes and transfersomes for topical delivery of Ginsenoside Rh1 from red ginseng: Characterization and in vitro evaluation. J Nanosci Nanotechnol 2015; 15(8): 5660-2.
[http://dx.doi.org/10.1166/jnn.2015.10462] [PMID: 26369134]
[31]
Wang H, Peng D, Xie J. Ginseng leaf-stem: Bioactive constituents and pharmacological functions. Chin Med 2009; 4(1): 20.
[http://dx.doi.org/10.1186/1749-8546-4-20] [PMID: 19849852]
[32]
Singh P, Singh H, Ahn S, et al. Pharmacological importance, characterization and applications of gold and silver nanoparticles synthesized by Panax ginseng fresh leaves. Artif Cells Nanomed Biotechnol 2017; 45(7): 1415-24.
[http://dx.doi.org/10.1080/21691401.2016.1243547] [PMID: 27855495]
[33]
Han X, Parker TL. Anti-inflammatory activity of clove (Eugenia caryophyllata) essential oil in human dermal fibroblasts. Pharm Biol 2017; 55(1): 1619-22.
[http://dx.doi.org/10.1080/13880209.2017.1314513] [PMID: 28407719]
[34]
Sugihartini N. prabandari, R., yuwono, T., & rahmawati, D. R. (2019). The anti-inflammatory activity of essential oil of clove (Syzygium aromaticum) in absorption base ointment with addition of oleic acid and propylene glycol as enhancer. Int J Appl Pharm 11(5): 106-9.
[http://dx.doi.org/10.22159/ijap.2019.v11s5.t0081]
[35]
Aman RM, Abu Hashim II, Meshali MM. Novel clove essential oil nanoemulgel tailored by taguchi’s model and scaffold-based nanofibers: phytopharmaceuticals with promising potential as cyclooxygenase-2 inhibitors in external inflammation. Int J Nanomedicine 2020; 15: 2171-95.
[http://dx.doi.org/10.2147/IJN.S246601] [PMID: 32280213]
[36]
Liangqian J, Yujuan W, Quifeng Y, Guoxiang L. Phycocyanin: A potential drug for cancer treatment. J Cancer 2017; 8(17): 3416-29.
[37]
Caddeo C, Chessa M, Vassallo A, et al. Extraction, purification and nanoformulation of natural phycocyanin (from Klamath algae) for dermal and deeper soft tissue delivery. J Biomed Nanotechnol 2013; 9(11): 1929-38.
[http://dx.doi.org/10.1166/jbn.2013.1741] [PMID: 24059092]
[38]
Potdar D, Hirwani RR, Dhulap S. Phyto-chemical and pharmacological applications of Berberis aristata. Fitoterapia 2012; 83(5): 817-30.
[http://dx.doi.org/10.1016/j.fitote.2012.04.012] [PMID: 22808523]
[39]
Kaur CD. Nimisha, Rizvi DA, Fatima Z, Neema. Antipsoriatic and anti-inflammatory studies of Berberis aristata extract loaded nanovesicular gels. Pharmacogn Mag 2017; 13(51) (Suppl. 3): 587.
[http://dx.doi.org/10.4103/pm.pm_210_17] [PMID: 29142419]
[40]
Puglia C, Cardile V, Panico AM, et al. Evaluation of monooleine aqueous dispersions as tools for topical administration of curcumin: Characterization, in vitro and ex vivo studies. J Pharm Sci 2013; 102(7): 2349-61.
[http://dx.doi.org/10.1002/jps.23605] [PMID: 23686742]
[41]
Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: In vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release 2005; 106(1-2): 99-110.
[http://dx.doi.org/10.1016/j.jconrel.2005.04.007] [PMID: 15935505]
[42]
Marianecci C, Rinaldi F, Di Marzio L, et al. Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models. Int J Nanomedicine 2014; 9: 635-51.
[PMID: 24493924]
[43]
Singh HP, Utreja P, Tiwary AK, Jain S. Elastic liposomal formulation for sustained delivery of colchicine: In vitro characterization and in vivo evaluation of anti-gout activity. AAPS J 2009; 11(1): 54-64.
[http://dx.doi.org/10.1208/s12248-008-9078-8] [PMID: 19191031]
[44]
Caddeo C, Díez SO, Pons R, Fernàndez BX, Fadda AM, Manconi M. Topical anti-inflammatory potential of quercetin in lipid-based nanosystems: in vivo and in vitro evaluation. Pharm Res 2014; 31(4): 959-68.
[http://dx.doi.org/10.1007/s11095-013-1215-0] [PMID: 24297068]
[45]
Marzio LD, Ventura CA, Cosco D, et al. Nanotherapeutics for antiinflammatory delivery. J Drug Deliv Sci Technol 2016; 32(B): 174-91.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy